
Sign up to save your podcasts
Or


Dr. Ifrah Zawar joins Being Patient Live Talks to discuss seizures, cognitive decline, and dementia. As she discussed in our article on seizures, epilepsy can accelerate cognitive decline, and the condition can also be mistaken for cognitive decline.
Lou Niles joins Being Patient Live Talks to discuss his experience taking part in the donanemab clinical trial. The monoclonal antibody drug was revealed to have promising results in late 2023 and is currently awaiting FDA approval.
Dr. Ifrah Zawar joins Being Patient Live Talks to discuss seizures, cognitive decline, and dementia. As she discussed in our article on seizures, epilepsy can accelerate cognitive decline, and the condition can also be mistaken for cognitive decline.
Clinical psychologist, educator, and author Dasha Kiper joins Being Patient Live Talks to discuss her book "Travelers to Unimaginable Lands." Using her experience as a caregiver and counselor and research on neurological and cognitive research, Kiper shares stories of caregivers and people living with dementia in the book. In particular, using stories and neurological research together, she can shed light on the pressures on caregivers.
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data to help researchers and drug developers understand what works, what doesn’t, and why. On Wednesday, January 24th, at 10:00 a.m. PT/1:00 p.m. ET, drug trial participant Bill Sasse, who was a participant in Eli Lilly’s clinical trial of experimental monoclonal antibody drug solanezumab, joins Being Patient Live Talks to discuss his experience with the drug trial. In March of 2023, solanezumab ultimately failed to hit its benchmarks in slowing cognitive decline and the trial was discontinued.
Award-winning dementia researcher and educator Dr. Nir Grossman joins Being Patient Live Talks to talk about the potential of cutting-edge medical technology like deep brain stimulation as an emerging approach to treating neurodegenerative diseases like Alzheimer’s.
🔥The 5 BIGGEST breakthroughs of 2023 in Alzheimer’s and dementia. 🚀
Award-winning dementia researcher and educator Dr. Nir Grossman joins Being Patient Live Talks to talk about the potential of cutting-edge medical technology like deep brain stimulation as an emerging approach to treating neurodegenerative diseases like Alzheimer’s.
The key to understanding Alzheimer’s disease could be in our genes. While the cause of Alzheimer’s is still unknown, mounting research shows that carrying multiple copies of certain genes — like genetic variant ApoE4 — can significantly increase the likelihood of developing Alzheimer’s. By studying genetics and gene therapy, scientists are learning more about how genes play a role in Alzheimer’s disease and what can be done for prevention.
Xanax and other benzodiazepines (“benzos”) are often prescribed to treat symptoms like agitation, anxiety, and depression in people living with dementia. Yet, these drugs come with significant side effects and safety concerns, especially for older adults living with dementia.
From the publisher's feed

2,027 Listeners

16 Listeners